文献速递心外重症与机械循环支持

HeartMate 3左心室辅助装置患者减少抗栓策略的安全性

Safety of reduced anti-thrombotic strategy in patients with HeartMate 3 left ventricular assist device.
PubMed 文献 · J Heart Lung Transplant · 2021-01-19

单中心回顾性研究分析161例HeartMate 3左心室辅助装置患者,其中50例(31.1%)接受减少抗栓治疗(RT),中位起始时间90.5天。RT最常见指征为消化道出血(29例,58.0%)。1年随访时RT组血栓事件发生率5.0%,从标准抗栓治疗(ST)转换为RT后大出血事件从1.252降至0.324事件/患者年(p=0.006)。

要点

  • RT组1年血栓事件率为5.0%,未增加血栓风险。
  • 转换为RT后大出血事件由1.252降至0.324事件/患者年(p=0.006)。
  • RT最常见指征为消化道出血,占58.0%。

核心结论

  • 在HeartMate 3左心室辅助装置患者中,减少抗栓治疗可减少出血而不增加血栓发生率。

主要发现

  • RT组中位起始时间为植入后90.5天,患者年龄更大且缺血性心力衰竭比例更高。
  • RT最常见指征为消化道出血(29例,58.0%)。
  • 1年随访时RT组血栓事件发生率为5.0%。
  • 从ST转换为RT后大出血事件从1.252降至0.324事件/患者年(p=0.006)。

关键数值与推荐

  • RT组1年血栓事件率5.0%。
  • 转换为RT后大出血事件从1.252降至0.324事件/患者年(p=0.006)。

临床怎么用

  • 对于HeartMate 3左心室辅助装置患者,可考虑减少抗栓治疗以减少出血,尤其有消化道出血等指征时。

局限性

  • 本研究为单中心回顾性研究,结果需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There are limited safety data on reduced anti-thrombotic therapy (RT) in patients with HeartMate 3 (HM3) left ventricular assist device (LVAD). We conducted a single-center, retrospective study of patients with HM3 managed with RT from November 2014 through January 2020. We analyzed baseline characteristics, RT indications, and bleeding and thrombotic complications. We found that 50 of 161 patients with HM3 (31.1%) received RT starting at a median time of 90.5 days after LVAD implantation. Patients on RT were older and more likely to have ischemic heart failure than patients on standard anti-thrombotic therapy (ST). The most common indication for RT was gastrointestinal bleeding (29 patients [58.0%]). At 1-year follow-up, 5.0% of patients on RT developed a thrombotic event. Switching patients from ST to RT reduced the occurrence of major bleeding from 1.252 to 0.324 events per patient-year (p = 0.006). In our population of patients with HM3 LVAD, RT reduces bleeding without increasing the incidence of thrombosis. Our retrospective study suggests that an upfront RT strategy in patients with HM3 may be beneficial and should be prospectively studied.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Marshall D, Sanchez J, Yuzefpolskaya M, et al. Safety of reduced anti-thrombotic strategy in patients with HeartMate 3 left ventricular assist device. J Heart Lung Transplant. 2021. PMID: 33551226. doi:10.1016/j.healun.2021.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。